• (13 Apr 2021) Heparin- prophylactic doses of LMWH significantly reduced mortality

  April 29, 2021

  Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation https://doi.org/10.1007/s11239-021-02429-z From the initial cohort of 422 patients, 264 were enrolled. Most (n = 156, 87.7%) received standard LMWH prophylaxis during hospitalization, with no significant difference… Continue reading "(13 Apr 2021) Heparin- prophylactic doses of LMWH significantly reduced mortality"

• (16 Mar 2021) Enoxaparin- associated with lower rates of mortality than unfractionated Heparin

  April 7, 2021

  Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients https://doi.org/10.1016/j.eclinm.2021.100774 We find that COVID-19 patients administered unfractionated Heparin but not Enoxaparin have higher rates of 28-day mortality (risk ratio: 4.3; 95% Confidence Interval [C.I.].:… Continue reading "(16 Mar 2021) Enoxaparin- associated with lower rates of mortality than unfractionated Heparin"

• (08 Jan 2021) Heparin-Inhospital heparin treatment was associated with lower mortality

  January 14, 2021

  Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study https://doi.org/10.1055/a-1347-6070 In a retrospective observational study, 2,574 unselected patients hospitalised in 30 clinical centres in Italy from February 19, 2020 to May 23, 2020 with… Continue reading "(08 Jan 2021) Heparin-Inhospital heparin treatment was associated with lower mortality"

• (05 Jan 2021) Heparin- LMWH was associated with lower all-cause in-hospital mortality

  January 6, 2021

  The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19 https://doi.org/10.1007/s10557-020-07133-3 Overall, 525 patients with COVID-19 enrolled with a median age of 64 years (IQR 19), and 49.33% men. Among these, 120 (22.86%) were… Continue reading "(05 Jan 2021) Heparin- LMWH was associated with lower all-cause in-hospital mortality"

• (04 Jan 2021) Enoxaprin- 60% reduction of mortality with higher doses

  January 6, 2021

  Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19 https://doi.org/10.1007/s11739-020-02585-9 Of 278 patients with Covid-19, 127 received prophylaxis with high enoxaparin doses and 151 with standard dosage. At 21 days, the incidence rate of death and clinical deterioration were… Continue reading "(04 Jan 2021) Enoxaprin- 60% reduction of mortality with higher doses"

• (29 Dec 2020) Heparin- LMWH was associated with a reduced risk of 30-day mortality

  January 2, 2021

  Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study https://doi.org/10.1093/ofid/ofaa563 Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint was achieved by 114 (36.2%)… Continue reading "(29 Dec 2020) Heparin- LMWH was associated with a reduced risk of 30-day mortality"

• (11 Oct 2020) Enoxaprin- associated with lower rates of thrombosis and mortality

  October 12, 2020

  Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients https://www.medrxiv.org/content/10.1101/2020.10.06.20208025v1 While retrospectively analyzing the complete electronic health records (EHRs) of 671 hospitalized COVID-19 patients administered either enoxaparin or unfractionated heparin,… Continue reading "(11 Oct 2020) Enoxaprin- associated with lower rates of thrombosis and mortality"

• (14 Sep 2020) Heparin- associated with a clinically significant improvement in a-line patency duration

  September 17, 2020

  A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients https://doi.org/10.1016/j.jcrc.2020.08.025 In this observational cohort study, patients >/=18 years with COVID-19 admitted to an ICU at one institution from March… Continue reading "(14 Sep 2020) Heparin- associated with a clinically significant improvement in a-line patency duration"

• (07 Sep 2020) LMW Heparin- D-dimer, and CRP levels were significantly improved in the LMWH group

  September 9, 2020

  The impact of the “low molecular weight heparin” administration on the clinical course of COVID-19 disease https://doi.org/10.3906/sag-2006-184 This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment on the clinical course of COVID-19. Participants… Continue reading "(07 Sep 2020) LMW Heparin- D-dimer, and CRP levels were significantly improved in the LMWH group"

• (28 Aug 2020) LMW Heparin-associated with lower incidence of mortality

  August 29, 2020

  Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients https://doi.org/10.3389/fphar.2020.01124 The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared in a retrospective study. Out of 450 patients, 361 received… Continue reading "(28 Aug 2020) LMW Heparin-associated with lower incidence of mortality"